DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger
DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger. Market participants are assessing the implications for related sectors and asset prices. Analysts note that this development may influence near-term trading sentiment and positioning across equities, rates, and commodities.
Meridian View
Meridian Intelligence View
Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.